Clinical Trial: A Multicenter, Open-label, Randomized Controlled Phase II Clinical Study of Ribociclib Combined with Aromatase Inhibitors (AI) Versus Chemotherapy Followed by Physician's Choice of Endocrine Therapy in Elderly Patients with Node-positive, Intermediate-to-high Risk HR+/HER2- Early Breast Cancer. (China)

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multicenter, Open-label, Randomized Controlled Phase II Clinical Study of Ribociclib Combined with Aromatase Inhibitors (AI) Versus Chemotherapy Followed by Physician's Choice of Endocrine Therapy in Elderly Patients with Node-positive, Intermediate-to-high Risk HR+/HER2- Early Breast Cancer.'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129445

Registration Time: 2026/08/05

Type: Interventional study

Primary Sponsor: The Second Affiliated Hospital of Dalian Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=316355

Published by HT D...